Reviva Pharmaceuticals Holdings, Inc. - Common Stock (RVPH)

Stay up-to-date with the latest market trends one hour before the close of the markets on Tuesday. Explore the top gainers and losers during today's session in our detailed report.

Curious to know what's happening on the US markets in the middle of the day on Tuesday? Join us as we explore the top gainers and losers in today's session.

Investors and traders are closely monitoring the gap up and gap down stocks in today's session on Tuesday. Let's explore the market movements and identify the stocks with significant gaps.

The FDA's approval of Bristol Myers Squibb's Cobenfy for schizophrenia opens doors for Reviva's brilaroxazine, a multi-receptor antipsychotic.

RVPH stock results show that Reviva Pharmaceuticals beat analyst estimates for earnings per share the second quarter of 2024.

RVPH stock results show that Reviva Pharmaceuticals beat analyst estimates for earnings per share the first quarter of 2024.

RVPH stock results show that Reviva Pharmaceuticals missed analyst estimates for earnings per share the fourth quarter of 2023.

These three companies are developing treatments for brain diseases that have a great deal of potential, making them top neuroscience stocks. 

Reviva Pharmaceuticals Holdings Inc (NASDAQ: RVPH) shares are surging after the company released topline results of its pivotal Phase 3 RECOVER trial evaluating brilaroxazine, a serotonin-dopamine signaling modulator in 

Reviva Pharmaceuticals Holdings Inc (NASDAQ: RVPH) announced the topline results of its pivotal Phase 3 RECOVER trial evaluating brilaroxazine, a serotonin-dopamine signaling modulator in 

It's time for another dive into the biggest pre-market stock movers this morning as we check out the latest news on Thursday!